Lee Kalowski Biography and Net Worth

PRESIDENT & CHIEF FINANCIAL OFFICER of Q32 Bio

Lee Kalowski, President and Chief Financial Officer of Q32 Bio, brings more than 20 years of biopharmaceutical experience with a focus on strategy, raising capital, and financial operations. Prior to his current role, Lee served as the Interim Chief Financial Officer of Q32 Bio. Before that, Lee was with Bicycle Therapeutics from 2017-2023, where he served as President and Chief Financial Officer, leading strategic finance and operations to support the company’s transition to a public clinical-stage biotech company. While at Bicycle, Lee helped raise $1 billion in capital, consisting of over $700 million in private, public, and non-dilutive financings including the company’s 2019 IPO and all subsequent financings. Prior to Bicycle, Lee was Chief Financial Officer of Tokai Pharmaceuticals where he helped lead the company’s IPO in 2014. Prior to Tokai, Lee served in global biotechnology equity research as a Senior Analyst at Credit Suisse, where he covered companies in the biopharmaceutical industry. Lee received a B.A. in biology and economics from Union College and an M.B.A. from The Wharton School of the University of Pennsylvania. Lee currently sits on the board of Aro Biotherapeutics.

What is Lee Kalowski's net worth?: The estimated net worth of Lee Kalowski is at least $712.93 thousand as of February 25th, 2026. Mr. Kalowski owns 35,943 shares of Q32 Bio stock worth more than $712,929 as of July 14th. This net worth estimate does not reflect any other investments that Mr. Kalowski may own. Learn More about Lee Kalowski's net worth.
How do I contact Lee Kalowski?: The corporate mailing address for Mr. Kalowski and other Q32 Bio executives is ONE PATRIOTS PARK, BEDFORD MA, 01730. Q32 Bio can also be reached via phone at 781-301-7277 and via email at [email protected]. Learn More on Lee Kalowski's contact information.
Has Lee Kalowski been buying or selling shares of Q32 Bio?: Lee Kalowski has not been actively trading shares of Q32 Bio in the last ninety days. Most recently, Lee Kalowski sold 3,995 shares of the business's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a transaction totalling $18,017.45. Following the completion of the sale, the chief financial officer now directly owns 35,943 shares of the company's stock, valued at $162,102.93. Learn More on Lee Kalowski's trading history.
Who are Q32 Bio's active insiders?: Q32 Bio's insider roster includes Lee Kalowski (PRESIDENT & CHIEF FINANCIAL OFFICER), and Jodie Morrison (CEO). Learn More on Q32 Bio's active insiders.
Are insiders buying or selling shares of Q32 Bio?: In the last year, Q32 Bio insiders bought shares 2 times. They purchased a total of 3,750,000 shares worth more than $30,000,000.00. In the last year, insiders at the sold shares 8 times. They sold a total of 66,008 shares worth more than $216,507.14. The most recent insider tranaction occured on May, 28th when Director Diyong Xu bought 1,875,000 shares worth more than $15,000,000.00. Insiders at Q32 Bio own 34.5% of the company. Learn More about insider trades at Q32 Bio.
Information on this page was last updated on 5/28/2026.

Lee Kalowski Insider Trading History at Q32 Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/25/2026	Sell	3,995	$4.51	$18,017.45	35,943
12/2/2025	Sell	9,072	$3.46	$31,389.12	39,938
8/26/2025	Sell	4,240	$1.80	$7,632.00	49,010

Lee Kalowski Buying and Selling Activity at Q32 Bio

Q32 Bio Company Overview

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Today's Range

Now: $19.43

$19.28

$23.57

50 Day Range

MA: $10.54

$5.14

$21.38

2 Week Range

Now: $19.43

$1.57

$23.57

Volume

2,487,088 shs

Average Volume

729,659 shs

Market Capitalization

$329.50 million

P/E Ratio

7.39

Dividend Yield

N/A

Beta

0.24